Phase 3 Clinical Trial for Sickle Cell Disease: Betty Pace, MD, received a $178K, 2-year award from Mast Therapeutics, Inc. for “MST-188-01: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double blind...
Phase 3 Clinical Trial for Sickle Cell Disease: Betty Pace, MD, received a $178K, 2-year award from Mast Therapeutics, Inc. for “MST-188-01: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double blind...